The compelling preclinical data in TNBC, particularly in ADC-resistant models, suggests azenosertib could address a growing unmet need as ADCs move into first-line TNBC treatment. This pipeline expansion potential, combined with strong validation of the ovarian cancer target population, could drive positive re-rating. Monitor for clinical trial initiation in TNBC and upcoming data from ongoing ovarian cancer studies.
ZNTL drugs
ZNTL drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 17 $4.64entry
- T+1 · 7mo ago −13.15%α −12.95% · $4.03
- T+5 · 7mo ago −14.22%α −14.78% · $3.98
- T+20 · 6mo ago −11.85%α −17.22% · $4.09
- T+60 · 4mo ago +2.80%α −3.34% · $4.77
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Zentalis Pharmaceuticals presented preclinical data at AACR 2026 showing that its investigational WEE1 inhibitor azenosertib demonstrates strong antitumor activity in triple-negative breast cancer (TNBC), including complete responses in ADC-resistant models. The company also presented real-world evidence confirming poor outcomes for Cyclin E1-positive ovarian cancer patients, reinforcing the unmet need for azenosertib in this population.
Key Facts
- Azenosertib combinations induced complete tumor responses in 7 of 8 mice (87.5%) in a TNBC model resistant to sacituzumab govitecan
- Prevented tumor progression in 8 of 8 mice for over 52 days vs. 100% progression within 30 days with enfortumab vedotin alone
- Azenosertib monotherapy showed 42-99% tumor growth inhibition across 12 TNBC models
- Cyclin E1-positive ovarian cancer patients had significantly worse outcomes: 13.2-14.9 months time to next treatment vs. 19.5 months for Cyclin E1-negative patients (p<0.002)
- Azenosertib has Fast Track Designation from FDA for Cyclin E1-positive platinum-resistant ovarian cancer
Financial Impact
Potential pipeline expansion into TNBC market, which could significantly increase peak sales potential beyond current ovarian cancer focus
Risk Factors
- Preclinical data may not translate to human clinical efficacy
- Competitive landscape in TNBC is rapidly evolving with multiple ADCs and targeted therapies in development
- Company has limited financial resources and may need to raise capital
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001725160-26-000020 |
| Exhibit: ex991aacr2026datapressrele.htm | 0001725160-26-000020 |
| Exhibit: ex993-jeongetal_realworl.htm | 0001725160-26-000020 |
| Exhibit: ex992-leeetalazenointnbc.htm | 0001725160-26-000020 |
| Document: 0001725160-26-000020-index-headers.html | 0001725160-26-000020 |
| Document: 0001725160-26-000020-index.html | 0001725160-26-000020 |
| Document: 0001725160-26-000020.txt | 0001725160-26-000020 |
Track record
18 reports on ZNTL
4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +51.42% at T+60 after the Aug 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $1.62 Now $1.60 −1.23% settles Feb 12
- Nov 9, 20267d ago 8-K Bearish 5/10 Entry $1.80 Now $1.60 +11.11% settles Feb 8
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $2.06 Now $1.60 −22.33% settles Jan 26
- Oct 18, 202629d ago Press Release Bullish 7/10 Entry $2.30 Now $1.60 −30.43% settles Jan 14
- Oct 1, 20266w ago Press Release Neutral 2/10 Entry $2.52 Now $1.60 −36.51% settles Dec 29
- Aug 14, 202613w ago 8-K Bearish 6/10 Entry $3.71 to $1.80 Now $1.60 +56.82% ▲ +51.42% +48.47% vs SPY
- Aug 13, 202613w ago Press Release Bearish 6/10 Entry $3.56 to $1.74 Now $1.60 +55.06% ▲ +51.12% +48.08% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.75 to $4.03 Now $1.60 −57.33% ▲ +7.47% +4.20% vs SPY
- Jun 1, 202624w ago Press Release Neutral 2/10 Entry $3.95 to $3.89 Now $1.60 −59.49% ▼ −1.52% −2.64% vs SPY
- May 21, 202625w ago Press Release Bullish 6/10 Entry $4.06 to $3.68 Now $1.60 −60.59% ▼ −9.36% −12.55% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers